Effects of liraglutide on weight, satiation, and gastric functions in obesity: a randomised, placebo-controlled pilot trial

Halawi, Houssam; Khemani, Disha; Eckert, Deborah J.; O’Neill, Jessica; Kadouh, Hoda C.; Grothe, Karen; Clark, Matthew M.; Burton, Duane D.; Vella, Adrian; Acosta, Andrés; Zinsmeister, Alan R.; Camilleri, Michael

doi:10.1016/s2468-1253(17)30285-6

Cited by 139 publications

(174 citation statements)

References 30 publications

Supporting

Mentioning

158

Contrasting

Unclassified

Order By: Relevance

“…Such an effect was previously described for GLP‐1 by Nauck et al and confirmed by another group with a prolonged infusion of GLP‐1 . A recent trial with liraglutide 3.0 mg investigating gastric emptying after a solid meal assessed by scintigraphy also demonstrated tachyphylaxis of liraglutide effects after 16 vs 5 weeks, although a delay in gastric emptying compared with placebo still remained after 16 weeks . In the present study, changes in gallbladder motility were not associated with changes in gastric emptying.…”

Section: Discussionsupporting

confidence: 72%

Effects of liraglutide on gallbladder emptying: A randomized, placebo‐controlled trial in adults with overweight or obesity

Nexøe-Larsen

Sørensen

Hausner

et al. 2018

Diabetes Obesity Metabolism

View full text Add to dashboard Cite

AimsTreatment with liraglutide 3.0 mg has been associated with gallbladder‐related adverse events. To conduct a single‐centre, double‐blind, 12‐week trial comparing the effect of 0.6 mg liraglutide and steady‐state liraglutide 3.0 mg with placebo on gallbladder emptying in adults with body mass index (BMI) ≥27 kg/m2 and without diabetes.MethodsParticipants were randomized 1:1 to once‐daily subcutaneous liraglutide (n = 26) or placebo (n = 26), starting at 0.6 mg with 0.6‐mg weekly increments to 3.0 mg, with nutritional and physical activity counselling. A 600‐kcal (23.7 g fat) liquid meal test was performed at baseline, after the first dose and after 12 weeks. The primary endpoint was the 12‐week maximum postprandial gallbladder ejection fraction (GBEFmax), measured over 240 minutes after starting the meal.ResultsBaseline characteristics were similar between groups (mean ± SD overall age 47.6 ± 10.0 years, BMI 32.6 ±3.4 kg/m2, 50% women). Mean 12‐week GBEFmax (treatment difference −3.7%, 95% confidence interval [CI] −13.1, 5.7) and area under the GBEF curve in the first 60 minutes (−390% × min, 95% CI −919, 140) did not differ for liraglutide 3.0 mg (n = 23) vs placebo (n = 24). The median (range) time to GBEFmax was 151 (11‐240) minutes with liraglutide 3.0 mg and 77 (22‐212) minutes with placebo. Similar findings were noted after the first 0.6‐mg liraglutide dose. Gastrointestinal disorders, notably nausea and constipation, were the most frequently reported adverse events.ConclusionsTreatment with liraglutide did not affect the GBEFmax but appeared to prolong the time to GBEFmax.

show abstract

Section: Discussionsupporting

confidence: 72%

Effects of liraglutide on gallbladder emptying: A randomized, placebo‐controlled trial in adults with overweight or obesity

Nexøe-Larsen

Sørensen

Hausner

et al. 2018

Diabetes Obesity Metabolism

View full text Add to dashboard Cite

show abstract

“…In the exenatide group, we had preselected participants with accelerated GE (GE T 1/2 82.4 ± 5.1 minutes). The effects of these GLP‐1 agents are published elsewhere . There was a significant correlation between the change in weight and GE at 30 days or 5 weeks ( r s = −.382, P = .004; Figure ).…”

Section: Resultsmentioning

confidence: 85%

“…We evaluated the genetic variations of GLP1R and TCF7L2 from two different published studies involving single‐center, double‐blinded, placebo‐controlled, randomized clinical trials: the first (ClinicalTrials.gov #NCT02160990) utilized exenatide, 5 μg BID administered for 30 days, in 20 obese individuals with rapid GE of solids (GE T 1/2 <90 minutes), and the second (ClinicalTrials.gov #NCT02647944) studied liraglutide, 3 mg/day, administered over 16 weeks in 40 obese individuals with normal or accelerated GE of solids . Further details of these trials are provided in the relevant publications and in Figures A and B.…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Allelic variant in the glucagon‐like peptide 1 receptor gene associated with greater effect of liraglutide and exenatide on gastric emptying: A pilot pharmacogenetics study

Vijayvargiya

Carlson

Malderen

et al. 2018

Neurogastroenterology Motil

View full text Add to dashboard Cite

show abstract

“…In our study, the reduction in TDD may be partially responsible for BW reduction. The effects of Lira on weight loss are also associated with delays in gastric emptying . It has been demonstrated that the administration of Lira can reduce the proportion of visceral adipose tissue .…”

Section: Discussionmentioning

confidence: 99%

Efficacy and safety of liraglutide added to insulin therapy in elderly patients with type 2 diabetes

Tonoike

Chujo

Noda

2018

Endocrino Diabet & Metabol

View full text Add to dashboard Cite

Summary Introduction The combination of GLP‐1 receptor agonists and insulin is effective in type 2 diabetes (T2D) treatment. However, its longitudinal efficacy and safety in elderly patients have not been established. We evaluated whether liraglutide (Lira) added to insulin therapy safely improved glycaemic control in T2D patients aged >65 years. Methods Twenty T2D patients receiving insulin were recruited, and Lira was added to their treatment regimen. Before and 6 months after Lira was added, we assessed the metabolic parameters and continuous glucose monitoring (CGM) data. Results Six months after Lira was added, the levels of HbA1c and glycated albumin and body weight were significantly improved, despite the daily doses and number of insulin injections per day being reduced. CGM analysis revealed that the SD and AUC of glucose >180 mg/dL were significantly decreased; the proportion of hypoglycaemic events was not increased. Conclusion Lira administration safely improved glycaemic control and reduced body weight. Lira added to insulin therapy may improve the quality of life in elderly T2D patients undergoing insulin therapy, especially those requiring social support.

show abstract

Effects of liraglutide on weight, satiation, and gastric functions in obesity: a randomised, placebo-controlled pilot trial

Cited by 139 publications

References 30 publications

Effects of liraglutide on gallbladder emptying: A randomized, placebo‐controlled trial in adults with overweight or obesity

Effects of liraglutide on gallbladder emptying: A randomized, placebo‐controlled trial in adults with overweight or obesity

Allelic variant in the glucagon‐like peptide 1 receptor gene associated with greater effect of liraglutide and exenatide on gastric emptying: A pilot pharmacogenetics study

Efficacy and safety of liraglutide added to insulin therapy in elderly patients with type 2 diabetes

Contact Info

Product

Resources

About